| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.51▲ | 1.51▲ | 1.51▲ | 1.66▼ | 1.73▼ |
| MA10 | 1.51▼ | 1.53▼ | 1.56▼ | 1.71▼ | 1.79▼ |
| MA20 | 1.57▼ | 1.62▼ | 1.66▼ | 1.76▼ | 2.01▼ |
| MA50 | 1.68▼ | 1.71▼ | 1.74▼ | 1.88▼ | 1.33▲ |
| MA100 | 1.75▼ | 1.78▼ | 1.76▼ | 2.04▼ | 1.04▲ |
| MA200 | 1.75▼ | 1.84▼ | 1.92▼ | 1.47▲ | 1.49▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▼ | -0.008▼ | -0.016▼ | -0.021▼ | -0.109▼ |
| RSI | 33.352▼ | 33.405▼ | 32.007▼ | 34.500▼ | 44.654▼ |
| STOCH | 41.204 | 25.195 | 15.740▼ | 10.760▼ | 18.221▼ |
| WILL %R | -66.667 | -82.609▼ | -88.889▼ | -91.704▼ | -95.436▼ |
| CCI | -43.223 | -57.042 | -73.684 | -195.437▼ | -124.211▼ |
|
Thursday, August 07, 2025 01:26 PM
IN8bio is developing a platform of cell therapies using gamma-delta T cells, a type of immune cell believed to help target and destroy cancer cells. Its current lead programs include INB-200 for ...
|
|
Monday, June 02, 2025 04:41 AM
INB-200 shows significantly improved progression-free survival in glioblastoma patients, with favorable safety profile and no serious toxicities reported. Repeated doses of INB-200 demonstrated an ...
|
|
Tuesday, March 18, 2025 05:12 AM
IN8bio, Inc., a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies for cancer and autoimmune diseases, will participate in the Immuno-Oncology 360° Conference 2025 from ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 16/12/25 | 1.55 | 1.565 | 1.445 | 1.50 | 74,040 |
| 15/12/25 | 1.72 | 1.7211 | 1.53 | 1.60 | 74,825 |
| 12/12/25 | 1.76 | 1.87 | 1.67 | 1.68 | 86,115 |
| 11/12/25 | 1.76 | 1.79 | 1.71 | 1.73 | 32,085 |
| 10/12/25 | 1.70 | 1.80 | 1.70 | 1.77 | 39,157 |
| 09/12/25 | 1.77 | 1.79 | 1.70 | 1.72 | 40,676 |
| 08/12/25 | 1.82 | 1.8285 | 1.77 | 1.78 | 26,476 |
| 05/12/25 | 1.85 | 1.8899 | 1.76 | 1.77 | 26,186 |
| 04/12/25 | 1.78 | 1.84 | 1.76 | 1.82 | 36,168 |
| 03/12/25 | 1.80 | 1.81 | 1.73 | 1.75 | 20,426 |
|
|
||||
|
|
||||
|
|